Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zeynep Eroglu

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
Journal for Immunotherapy of Cancer|March 25, 2025
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanomaLi Zhou, Milton Jose Barros E Silva, Edward Hsiao, et al.
Nature Medicine|August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trialAri VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
Nature Medicine|August 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Transplantation and Cellular Therapy|December 20, 2025
Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patientsLilit Karapetyan, Joel Kuriakose, Elizabeth DiMaggio, et al.
The Lancet. Oncology|May 17, 2021
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trialAlexander J Stratigos, Aleksandar Sekulic, Ketty Peris, et al.
Lancet (London, England)|September 15, 2022
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trialSungjune Kim, Evan Wuthrick, Dukagjin Blakaj, et al.
Nature Medicine|August 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2021
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysisSimone M Goldinger, Kristina Buder-Bakhaya, Serigne N Lo, et al.
Eclinicalmedicine|October 23, 2025
Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based studyJessica S W Borgers, Douglas B Johnson, Elisabeth Livingstone, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Journal for Immunotherapy of Cancer|March 25, 2025
FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanomaLi Zhou, Milton Jose Barros E Silva, Edward Hsiao, et al.
Nature Medicine|August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trialAri VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
Nature Medicine|August 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Transplantation and Cellular Therapy|December 20, 2025
Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patientsLilit Karapetyan, Joel Kuriakose, Elizabeth DiMaggio, et al.
The Lancet. Oncology|May 17, 2021
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trialAlexander J Stratigos, Aleksandar Sekulic, Ketty Peris, et al.
Lancet (London, England)|September 15, 2022
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trialSungjune Kim, Evan Wuthrick, Dukagjin Blakaj, et al.
Nature Medicine|August 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2021
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysisSimone M Goldinger, Kristina Buder-Bakhaya, Serigne N Lo, et al.
Eclinicalmedicine|October 23, 2025
Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry-based studyJessica S W Borgers, Douglas B Johnson, Elisabeth Livingstone, et al.
Pageof 12